An Overview of Results of World-Wide Clinical Trials with Cefadroxil
| Autor: | P J Santella, E. Berman, B. Tanrisever |
|---|---|
| Rok vydání: | 1978 |
| Předmět: |
Male
Gastrointestinal Diseases Cephalosporin Pharmacology medicine.disease_cause 030226 pharmacology & pharmacy Biochemistry 0302 clinical medicine Skin Diseases Infectious Child Respiratory Tract Infections Clinical Trials as Topic Respiratory tract infections Bacterial Infections General Medicine Middle Aged Infectious Diseases Child Preschool 030220 oncology & carcinogenesis Urinary Tract Infections Female Bone Diseases Genital Diseases Male medicine.drug Adult Microbiology (medical) medicine.medical_specialty Adolescent medicine.drug_class Microbiology 03 medical and health sciences Pharmacokinetics Sepsis Internal medicine Streptococcus pneumoniae medicine Humans Cephradine Aged business.industry Genitourinary system Biochemistry (medical) Infant Newborn Infant Cell Biology Cephalosporins Clinical trial Cefadroxil business Genital Diseases Female |
| Zdroj: | Journal of International Medical Research. 6:441-451 |
| ISSN: | 1473-2300 0300-0605 |
| DOI: | 10.1177/030006057800600604 |
| Popis: | Cefadroxil, a new semisynthetic oral cephalosporin, is absorbed similarly by fasted and non-fasted subjects, produces sustained serum levels and is eliminated at a relatively slow rate. These pharmacokinetic properties permit less frequent and more convenient dosage scheduling than cephalexin and cephradine and consequently greater patient compliance. Cefadroxil was evaluated for safety in 1051 patients and for efficacy in 1030 patients. Overall it achieved a 91.8% rate of clinical success resulting from 881 complete cures and sixty-five clinical cures. Among 363 patients with respiratory tract infections and 471 patients with genito-urinary tract infections, cefadroxil treatment produced 97.5% and 84.5% clinical success, respectively. In the remaining infectious diseases treated, cefadroxil therapy resulted in 99.0% clinical success. Cefadroxil eradicated 87% of 1110 pathogens isolated, among which the most predominant pathogens were Staphylococcus aureus, β-haemolytic streptococci, Streptococcus pneumoniae, Escherichia coli and Proteus mirabilis. Drug-related side-effects were reported in 7.2% of the patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|